Glycogen Storage Disease (GSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Glycogen Storage Disease (GSD) Market Outlook

Thelansis’s “Glycogen Storage Disease (GSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glycogen Storage Disease (GSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Glycogen Storage Disease (GSD) Overview

Glycogen storage diseases (GSDs) are hereditary disorders resulting from inborn errors in carbohydrate metabolism. These disorders lead to abnormal glycogen storage and are categorized as GSDs. They are assigned numerical classifications based on identifying the enzyme defect responsible for the condition. Clinical symptoms can manifest from infancy to adulthood. GSDs can arise due to the accumulation of toxic glycogen and the inability to convert glycogen into energy. However, in all cases, they result in an inability to utilize or store glycogen. There are various types of glycogen storage diseases, with the following being the most prevalent:

Glycogen storage disorders primarily affecting the liver encompass:

• Glycogen synthase-2 deficiency (GSD type 0a)
• Glucose-6-phosphatase deficiency (GSD type Ia)
• Glucose-6-phosphate transporter deficiency (GSD type Ib)
• Glycogen debrancher deficiency (GSD type III)
• Glycogen branching enzyme deficiency (GSD type IV)
• Liver phosphorylase deficiency (GSD type VI)
• Phosphorylase kinase deficiency (GSD type IXa)
• GLUT2 deficiency, also known as Fanconi-Bickel disease

Glycogen storage disorders primarily affecting skeletal muscles include:

• Muscle phosphorylase deficiency (GSD type V)
• Phosphofructokinase deficiency (GSD type VII)
• Phosphoglycerate mutase deficiency (GSD type X)
• Lactate dehydrogenase A deficiency (GSD type XI)
• Aldolase A deficiency (GSD type XII)
• Beta-enolase deficiency (GSD type XIII)
• Phosphoglucomutase-1 deficiency (GSD type XIV)

Glycogen storage disorders affecting both skeletal and cardiac muscles include:

• Lysosomal acid maltase deficiency (GSD type IIa)
• Lysosome-associated membrane protein 2 deficiency (GSD type IIb)
• Glycogenin-1 deficiency (GSD type XV)
• Muscle glycogen synthase deficiency (GSD type 0b)

With early detection and proper management, most GSDs have a favorable prognosis. Effective dietary management reduces complications associated with hypoglycemia and has shown promise in ameliorating renal dysfunction in GSD type I patients. In rare instances, end-stage renal disease necessitating kidney transplantation may arise in GSD type Ib patients. For individuals with GLUT2 deficiency, an antiketogenic diet can significantly reduce liver size and glycogen content. In GSD type Ia patients, growth delays, short stature, renal dysfunction, hypertriglyceridemia, and hepatocellular carcinoma may occur. On the other hand, GSD type Ib can lead to recurrent bacterial infections due to neutropenia. GSD type IV is associated with progressive liver failure and cirrhosis. Patients with GSD type II may develop cardiomyopathy and limb-girdle dystrophy, while GSD type III often presents with hypertrophic cardiomyopathy as a classic complication.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Glycogen Storage Disease (GSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034